在患有发育性和性脑病变的患者中,soticlestat的群体药理动力学,酶占用率和药理动力学建模
Wei Yin1, Axel Facius2, Mahnaz Asgharnejad1
1Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.
Clinical and translational science
|March 6, 2024
概括
一种CH24H抑制剂Soticlestat显示了针对发育性和性脑病变 (如德拉维特综合征和伦诺克斯-加斯托综合征) 的最佳剂量策略. 这种基于模型的方法确保了对这些罕见的病状况的有效治疗.
科学领域:
- 药理学和临床药理学
- 神经科学是一个神经科学.
- 生物统计学 生物统计学
背景情况:
- 索蒂克利斯塔特 (TAK-935) 是一种新的胆固醇24-基酶 (CH24H) 的选择性抑制剂.
- 它正在第三阶段开发,用于发育性和性脑病变 (DEE),包括德拉维特综合征 (DS) 和伦诺克斯-加斯托综合征 (LGS).
- 一个先前的模型描述了soticlestat的药理动力学 (PK),酶占用率 (EO) 和健康志愿者的药理动力学 (PD).
研究的目的:
- 将现有的PK/EO/PD模型扩展到DEE患者.
- 为了识别和描述soticlestat的药理动力学和药理动力学概况的变异性来源.
- 用基于模型的模拟来优化III期临床试验的剂量策略.
主要方法:
- 人口PK (PopPK) 和PK/EO/PD分析是使用I期和II期试验的数据进行的.
- 使用了一个带有效果部位隔间的双隔间PK模型.
- 一个半机械抑制间接反应模型将soticlestat度与24S-hydroxycholesterol水平联系起来.
主要成果:
- 最终的PopPK和PK/EO/PD模型准确地描述了soticlestat在健康志愿者和DEE患者中的PK,EO和PD.
- 共变量分析确定了影响药物暴露和效果的变异性的关键来源.
- 基于模型的模拟成功开发了四个体重范围内的优化儿科剂量策略.
结论:
- 开发的种群模型提供了关于soticlestat在DEE患者的行为的一个可靠描述.
- 从这些模型中获得的优化剂量策略将支持DS和LGS的高效III期试验执行.
- 这项工作有助于为罕见的儿科症疾病进行临床开发.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
137
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
137
Pharmacokinetic Models: Comparison and Selection Criterion
71
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
71
Pharmacokinetic Models: Overview
682
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
682
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
296
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
296


